Potential of Enoxaparin to Maintain A-V Shunt Patency According to the SEP Protocol
A newly published study by authors from Singapore focused on the ability of the SEP protocol – short-term low-dose enoxaparin administration based on body weight – to maintain the patency of an arteriovenous (A-V) shunt after recurrent thrombosis.
Risk of A-V Shunt Thrombosis
An arteriovenous shunt (bypass) is essential for long-term hemodialysis in individuals with end-stage renal disease (ESRD). However, the problem with A-V shunts is their susceptibility to stenosis and thrombosis. Loss of patency then contributes to significant morbidity in these patients and increased costs of their care. The risk of loss of A-V shunt patency is particularly high in patients with recurrent thrombosis within 90 days after successful thrombectomy.
The optimal pharmacotherapy to maintain A-V shunt patency is not known. The cited study therefore evaluated the efficacy and safety of short-term low-dose subcutaneous enoxaparin based on body weight, the so-called SEP protocol, which was jointly developed by hematologists, neurologists, and vascular surgeons, to maintain A-V shunt patency after recurrent thrombosis.
Study Methods − SEP Protocol with Enoxaparin
The enoxaparin dose in the SEP protocol was derived from the patient's weight and the administration length was 4 weeks. This protocol was prescribed to patients with recurrent A-V shunt thrombosis within 90 days after successful thrombectomy. Twenty-five patients were included in prospective follow-up. Contraindications to using the SEP protocol included the presence of active bleeding, concurrent anticoagulant therapy, or untreated congenital bleeding disorders. The prescribed enoxaparin doses were 20 mg for patients weighing < 50 kg, 40 mg for those weighing 50−100 kg, and 60 mg for patients with higher weights.
Results
The average age of patients was 66.4 ± 10.2 years, with men comprising 60% of the cohort. The A-V shunt had been in place for an average of 1.4 years (0.6−5.6 years), with 40% of the subjects having an autologous shunt. The average enoxaparin dose was 36.0 ± 8.2 mg or 0.64 ± 0.1 mg/kg/day, and the average administration duration was 30 days (interquartile range [IQR] 27.5−31.0). One patient experienced a minor bleeding complication (atraumatic gum bleeding that stopped spontaneously).
Kaplan-Meier analysis showed that while the average time to thrombosis before using the SEP protocol was 27.3 days (95% confidence interval [CI] 17.9−36.7 days), after using this protocol it averaged 183.5 days (95% CI 100.1−266.9 days; p < 0.001). Various previous thrombectomy procedures (administered thrombolytics, use of mechanical thrombectomy devices, drug-coated balloons, and stent grafts) did not significantly affect the benefits of the SEP protocol.
Conclusion
This study demonstrated that the SEP protocol with 4-week administration of low-dose subcutaneous enoxaparin based on patient weight is a feasible and safe method of thromboprophylaxis that prolongs A-V shunt patency after recurrent thrombosis.
(eza, zza)
Source: Gan CH, Tan RY, Cheong MA, et al. Efficacy and safety of low dose, weight based subcutaneous enoxaparin protocol in recurrent arteriovenous access thrombosis. J Vasc Access 2023 Sep 19: 11297298231194102, doi: 10.1177/11297298231194102 [Epub ahead of print].
Did you like this article? Would you like to comment on it? Write to us. We are interested in your opinion. We will not publish it, but we will gladly answer you.
